SIB SWISS INSTITUTE OF BIOINFORMATICS

Their core work

SIB is Switzerland's national bioinformatics infrastructure hub, providing computational biology expertise, databases, and data analysis services to life science research across Europe. They specialize in making complex biological and clinical datasets — genomics, proteomics, metabolomics — interoperable and FAIR-compliant, enabling large-scale multi-partner studies. Their core contribution to EU projects is bioinformatics platform development, data integration, and advanced computational analysis for health research, from diabetes and cancer to rare diseases and neuroscience. They are the organization others call when they need someone to make sense of massive, heterogeneous biomedical data.

What they specialise in

How they've shifted over time

In the early period (2015–2018), SIB's H2020 work centered on computational neuroscience (Human Brain Project) and foundational bioinformatics infrastructure (ELIXIR), with strong keywords around brain simulation, neuroinformatics, and high-performance computing. From 2019 onward, their focus shifted decisively toward health data — FAIR data management, cancer immunoprofiling, rare diseases, and clinical cohort federation became dominant themes. The neuroscience thread continued but was overtaken by a growing portfolio in precision medicine, genomics, and disease-specific data platforms.

SIB is moving from general computational biology infrastructure toward disease-specific data platforms, particularly in cancer immunoprofiling and metabolic diseases, making them an increasingly valuable partner for clinical data-intensive consortia.

How they like to work

SIB operates exclusively as a participant or third party — they have never coordinated an H2020 project, preferring to contribute specialized bioinformatics expertise to large, multi-partner consortia. With 505 unique partners across 39 countries, they are a highly connected hub organization that rarely repeats the same consortium, instead plugging into diverse research networks wherever computational biology expertise is needed. This makes them easy to work with as a reliable specialist partner, though those seeking a consortium leader should look elsewhere.

SIB has collaborated with 505 unique partners across 39 countries, giving them one of the broadest bioinformatics networks in Europe. Their partnerships span from major research hospitals and universities to pharmaceutical companies via IMI-linked projects like BEAt-DKD and Hypo-RESOLVE.

What sets them apart

SIB occupies a rare position as a nationally mandated bioinformatics institute that is neither a university nor a company — it serves as Switzerland's central hub for computational biology, giving it institutional stability and deep technical bench strength. Their combination of FAIR data expertise with domain knowledge in diabetes, neuroscience, and oncology means they can handle both the infrastructure and the scientific interpretation, unlike pure IT providers. For consortium builders, SIB brings credibility, a 500+ partner network, and the ability to integrate heterogeneous biomedical data across clinical sites — a persistent bottleneck in multi-center health projects.

Highlights from their portfolio

• IMMUcan
  Largest single EC contribution (EUR 1.77M) and longest project duration (2019–2026), reflecting SIB's deep investment in cancer immunoprofiling across five cancer types.
• ELIXIR-EXCELERATE
  Second-largest funding (EUR 1.46M) and foundational to SIB's role as a European life science data infrastructure node — established their FAIR data credentials.
• SOPHIA
  EUR 857K for obesity phenotype stratification using federated databases — represents SIB's growing role in metabolic disease precision medicine with real clinical impact potential.